The combination of efatutazone (PPARγ agonist) with T0901317 resulted in the reduced proliferation of lung cancer cells via targeting the PPARγ/LXRα/ABCA1 pathway (Ni et al., 2018). Here, PPARG is linked to lung carcinoma.